Page 97 - 《中国药科大学学报》2026年第2期

第 57 卷第 2 期 李佳慧，等：载厚朴酚达妥西单抗及三苯基膦双重修饰免疫脂质体对神经母细胞瘤的靶向治疗作用 223

dria-targeted drug and drug-free agents for cancer therapy[J]. high-risk and metastatic neuroblastoma[J]. Biomolecules, 2022,
Cancers (Basel), 2019, 12(1): 4-24. 12(3): 358.
[8] Khan MS, Jaswanth Gowda BH, Almalki WH, et al. Unravel- [20] Wen HY, Zhou SQ, Song JC. Induction of apoptosis by mag-
ling the potential of mitochondria targeted liposomes for en- nolol via the mitochondrial pathway and cell cycle arrest in re-
hanced cancer treatment[J]. Drug Discov Today, 2024, 29(1): nal carcinoma cells[J]. BiochemBiophys Res Commun, 2019,
103819. 508(4): 1271-1278.
[9] Shi JY, Wang HL, Wang YH, et al. Mitochondrion-targeting [21] Hashida M. Advocation and advancements of EPR effect theo-
and in situ photocontrolled protein delivery via photocages[J]. J ry in drug delivery science: a commentary[J]. J Control Release,
PhotochemPhotobiol B, 2023, 238: 112624. 2022, 346: 355-357.
[10] Cheng X, Feng D, Lv J, et al. Application prospects of triph- [22] Sun W, Han C, Ge R, et al. Sialic acid conjugate-modified
enylphosphine-based mitochondria-targeted cancer therapy[J]. cationic liposomal paclitaxel for targeted therapy of lung metas-
Cancers (Basel), 2023, 15(3): 666. tasis in breast cancer: what a difference the cation content
[11] Ye L, Yao Q, Xu FN, et al. Preparation and antitumor activity makes[J]. Mol Pharm, 2024, 21(4): 1625-1638.
of triphenylphosphine-based mitochondrial targeting polylactic [23] Luo ZL, Lin Y, Zhou XL, et al. Biomineral-binding liposomes
acid nanoparticles loaded with 7-hydroxyl coumarin[J]. J Bio- with dual antibacterial effects for preventing and treating dental
mater Appl, 2022, 36(6): 1064-1075. caries[J]. Biomater Sci, 2023, 11(17): 5984-6000.
[12] Lu HB, Tong WF, Jiang MX, et al. Mitochondria-targeted mul- [24] Guo XH, Mei Q, Xing YB, et al. Preparation and cytotoxicity of
tifunctional nanoprodrugs by inhibiting metabolic reprogram- poly (DL-lactide-co-glycolide) microspheres encapsulating 2-
ming for combating cisplatin-resistant lung cancer[J]. ACS methoxyestradiol[J]. Drug Deliv, 2012, 19(3): 143-148.
Nano, 2024, 18(32): 21156-21170. [25] Guo WX, Hu LF, Feng YH, et al. Evaluation of nanoparticle
[13] Hai YR, Fan RM, Zhao T, et al. A novel mitochondria-target- stability under blood flow shear[J]. Langmuir, 2022, 38(41):
ing DHODH inhibitor induces robust ferroptosis and alleviates 12731-12738.
immune suppression[J]. Pharmacol Res, 2024, 202: 107115. [26] Gholizadeh S, Dolman EM, Wieriks R, et al. Anti-GD2 im-
[14] Liu SJ, Jiang Y, Cheng XB, et al. Mitochondria-targeting munoliposomes for targeted delivery of the survivinin-
nanozyme for catalytical therapy and radiotherapy with activa- hibitorsepantroniumbromide (YM155) to neuroblastoma tumor
tion of cGAS-STING[J]. Colloids Surf B Biointerfaces, 2024, cells[J]. Pharm Res, 2018, 35(4): 85.
244: 114137. [27] Sainaga Jyothi VGS, Bulusu R, Rao BVK, et al. Stability char-
[15] Kianamiri S, Dinari A, Sadeghizadeh M, et al. Mitochondria- acterization for pharmaceutical liposome product development
targeted polyamidoamine dendrimer-curcumin construct for with focus on regulatory considerations: an update[J]. Int J
hepatocellular cancer treatment[J]. Mol Pharm, 2020, 17(12): Pharm, 2022, 624: 122022.
4483-4498. [28] Nsairat H, Ibrahim AA, Jaber AM, et al. Liposome bilayer sta-
[16] Chen QZ, Qian QP, Xu HB, et al. Mitochondrial-targeted metal- bility: emphasis on cholesterol and its alternatives[J]. J Lipo-
phenolic nanoparticles to attenuate intervertebral disc degenera- some Res, 2024, 34(1): 178-202.
tion: alleviating oxidative stress and mitochondrial [29] Abdalla AME, Xiao L, Ullah MW, et al. Current challenges of
dysfunction[J]. ACS Nano, 2024, 18(12): 8885-8905. cancer anti-angiogenic therapy and the promise of nanothera-
[17] Zafar A, Wang W, Liu G, et al. Molecular targeting therapies peutics[J]. Theranostics, 2018, 8(2): 533-548.
for neuroblastoma: progress and challenges[J]. Med Res Rev, [30] Panosyan WS, Panosyan DE, Koster J, et al. Anti-GD2 im-
2021, 41(2): 961-1021. munoliposomes loaded with oxamate for neuroblastoma[J]. Pe-
[18] Nazha B, Inal C, Owonikoko TK. Disialoganglioside GD2 ex- diatr Res, 2023, 94(2): 458-461.
pression in solid tumors and role as a target for cancer [31] Ekmekcioglu A, Gok O, Oz-Arslan D, et al. Mitochondria-tar-
therapy[J]. Front Oncol, 2020, 10: 1000. geted liposomes for drug delivery to tumor mitochondria[J].
[19] Chan GC, Chan CM. Anti-GD2 directed immunotherapy for Pharmaceutics, 2024, 16(7): 950.